Xarelto Bleeding Risks May Not be Minimized with Monitoring, Australian Regulators Determine
Australian regulators are questioning whether regular monitoring would alleviate Xarelto bleeding risks, due to the failure of drug manufacturers to conduct sufficient testing of their products. In addition to rivaroxaban (Xarelto), regulators evaluated risks associated with apixaban (Eliquis) and dabigatran (Pradaxa). These drugs all fall... Read More